ALDEYRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.95 USD | -3.42% |
|
+4.77% | +12.54% |
Presenter SpeechTodd Brady (Executives)Welcome to the 2022 Aldeyra Therapeutics Research and D...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Calendar
2024-06-03
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.95
USD
Average target price
9.25
USD
Spread / Average Target
+134.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.54% | 235M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -14.15% | 21.84B | |
| -1.05% | 21.96B | |
| -5.29% | 19.21B | |
| -38.29% | 17.71B | |
| -4.16% | 18.08B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- ALDX Stock
- News Aldeyra Therapeutics, Inc.
- Transcript : Aldeyra Therapeutics, Inc. - Special Call
